About Kodiak Sciences
Kodiak Sciences is a company based in Palo Alto (United States) founded in 2009. Kodiak Sciences has raised $35.84 million across 3 funding rounds from investors including Perceptive Advisors and ArrowMark Partners. The company has 109 employees. Kodiak Sciences offers products and services including Tarcocimab Tedromer, KSI-501, and KSI-101. Kodiak Sciences operates in a competitive market with competitors including argenx, MacroGenics, Alexion, Zai Lab and Visterra, among others.
- Headquarter Palo Alto, United States
- Employees 109
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website kodiak.com
- Social LinkedIn X
- Legal Name Kodiak Sciences Inc
- Net Profit-$229.97 M (USD)-30.51as on Dec 31, 2025
- EBITDA-$206.16 M (USD)-28.73as on Dec 31, 2025
- Total Equity Funding$35.84M (USD)
in 3 rounds
- Latest Funding Round$33M (USD), Debt – Conventional
Apr 2018
- InvestorsPerceptive Advisors
& 1 more
- Employee Count109
Products & Services of Kodiak Sciences
Kodiak Sciences offers a comprehensive portfolio of products and services, including Tarcocimab Tedromer, KSI-501, and KSI-101.
Provides durable treatment for retinal vascular diseases through biopolymer conjugates.
Targets inflammation and permeability in high-prevalence retinal conditions.
Treats macular edema linked to inflammation in retinal disorders.
Funding Insights of Kodiak Sciences
Kodiak Sciences has successfully raised a total of $35.84M across 3 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $33 million completed in April 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $35.84M
- Total Rounds 3
- Last Round Debt – Conventional — $33M
- First Round $1.84M
(Jul 2009)
- Investors Count 2
All 3 funding rounds of Kodiak Sciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2018 | $33M | Debt – Conventional | – | – | |
| Mar 2016 | $34M | Series B | – | – | – |
| Jul 2009 | $1.84M | Seed | – | – | – |
2 investors in total: 2 institutional.
Investors in Kodiak Sciences
Kodiak Sciences has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Perceptive Advisors and ArrowMark Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Diversified asset management services are provided to investors. | 2007 | arrowmarkpartners.com | Denver, United States |
Investor details for Kodiak Sciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Kodiak Sciences
70 people are tracked at Kodiak Sciences (25 in leadership, 13 in board & advisors, 32 in team); the tracked headcount is 109.
| Name | Role | Group |
|---|---|---|
Javier Ruiz | Director, Chemical Development And Manufacturing | Leadership |
Victor Perlroth | Chairman & CEO | Leadership |
Laurent Ducry | Vice President, Biologics Development and Manufacturing | Leadership |
Phil Schwartz | Director, Finance Operations | Leadership |
Kim Williams | Senior Director, Discovery Medicine | Leadership |
Andreas Zurbriggen | Senior Director, Drug Substance Development And Manufacturing | Leadership |
Fernando Correa | Executive Director | Leadership |
Pablo Velazquez-Martin | Vice President, Clinical Research and Translational Medicine | Leadership |
Bernd Jandeleit | Vice President, Chemistry | Leadership |
Tracy Chien | VP, Corporate Controller | Leadership |
Gorton Chiu | VP, Finance | Leadership |
John Borgeson | Senior Vice President and Chief Financial Officer | Leadership |
Cindy Ressi | Associate Director, Business Operations | Leadership |
Jan Erik Rau | Director - Head Of CMC Analytics | Leadership |
Mariann Bresnahan | Associate Director Of Finance & Operations At Kodiak Sciences | Leadership |
Gorton C. | Vice President, Finance | Leadership |
J. Pablo Velazquez-Martin | Chief Medical Officer | Leadership |
Ann Studdert Rn, Msn | Senior Director Clinical Science And Development Operations | Leadership |
Daniel Janer Vasquez | Executive Director Clinical Sciences | Leadership |
Wendy Ko | Senior Director, Head Of Clinical Operations | Leadership |
50 more people are available in the full profile.
Complete people profiles for Kodiak Sciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Kodiak Sciences
Kodiak Sciences is a publicly listed company on the NASDAQ with ticker symbol KOD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date04 Oct 2018
- Listed onNASDAQ: KOD
- Listed entityKodiak Sciences Inc
- Exchange sectorHealth technology
- ISINUS50015M1099
- Share price$94.26 (+3.49% on the day) · 2026-10-08
- Market capitalisation$5.92B
- EPS (diluted, trailing year)$-4.19
- Volume (last session)1,528,760
Financials of Kodiak Sciences
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | – | -$230.0M | -$206.2M |
| 2024 | – | -$176.2M | -$160.1M |
| 2023 | – | -$260.5M | -$251.4M |
| 2022 | – | -$333.8M | -$330.4M |
| 2021 | – | -$267.0M | -$258.3M |
Detailed financial statements for Kodiak Sciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Kodiak Sciences
4 dated milestones of Kodiak Sciences across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Kodiak Sciences is founded.
- Funding First funding round of $1.8M.
- Funding Latest funding round, Debt – Conventional, of $33.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Kodiak Sciences
Kodiak Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as argenx, MacroGenics, Alexion, Zai Lab and Visterra, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| argenx.com | 2008 | Ghent, Belgium | $61.9M | 355 | Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | |
| macrogenics.com | 2000 | Rockville, United States | $126.02M | 339 | A biopharmaceutical company focused on cancer therapeutics development. | |
| alexion.com | 1992 | Zurich, Switzerland | $8M | 1 | Therapies for rare and devastating diseases are developed by Alexion. | |
| zailaboratory.com | 2013 | Shanghai, China | $160M | – | Antibody-based therapies for cancers and inflammatory diseases are developed. | |
| visterrainc.com | 2007 | Cambridge, United States | $116.17M | 79 | Developer of monoclonal antibodies against infectious diseases | |
| bighatbio.com | 2019 | San Carlos, United States | $148.41M | – | Antibody therapies are developed through machine learning and synthetic biology. | |
| scholarrock.com | 2012 | Cambridge, United States | $103.3M | 150 | Antibody-based drugs for primary myopathies are developed and targeted. | |
| iggenix.com | 2019 | San Francisco, United States | $75M | – | Therapeutic solutions for food allergies are developed via antibody platforms. |
Detailed competitors of Kodiak Sciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Kodiak Sciences
The website of Kodiak Sciences (kodiak.com) receives about 6.6K visits a month and ranks #3,255,686 among all websites worldwide, #4,279 in Biotechnology and Pharmaceuticals.
- Monthly visits6.6K
▲ 7.5% vs previous month
- Unique visitors3.1K
per month
- Global rank#3,255,686
among all websites
- Category rank#4,279
Health · Biotechnology and Pharmaceuticals
- Bounce rate49%
- Pages per visit1.7
- Average visit59 sec
- DevicesDesktop 39% · Mobile 61%
Latest news on Kodiak Sciences
Complete news archive for Kodiak Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Kodiak Sciences
10 companies that operate in the same segment as Kodiak Sciences (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Kodiak Sciences
Kodiak Sciences was founded in 2009.
Kodiak Sciences is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Kodiak Sciences is a funded company, having raised a total of $35.84M across 3 funding rounds to date. The company's 1st funding round was a Seed of $1.84M, raised on Jul 2009.
Kodiak Sciences has 109 employees.
The company was founded in 2009 in Palo Alto, United States, and operates in the biotechnology sector. Focus is placed on developing therapeutics for retinal diseases, with two candidates in clinical stages: KSI-301 targeted at age-related macular degeneration and KSI-501 for dry age-related macular degeneration. These products are based on proprietary antibody bioconjugate platforms, supporting treatment advancements in ophthalmology.
Kodiak Sciences's top competitors include argenx, Zai Lab and MacroGenics.
Kodiak Sciences offers Tarcocimab Tedromer, KSI-501, and KSI-101.
Yes, Kodiak Sciences is publicly traded on NASDAQ under the ticker symbol KOD.
Kodiak Sciences has 2 investors. Key investors include Perceptive Advisors, and ArrowMark Partners.
Kodiak Sciences operates through Kodiak Sciences Inc..